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Background: Growth-curves are an important tool for evaluating the anthropometric development in pediatrics.
The different growth-curves available are based in different populations, what leads to different cut-offs.
Pediatric obesity tracks into adulthood and is associated with increased cardiovascular risk. The accurate assessment
of a child nutritional status using growth-curves can indicate individuals that are either obese or in risk of becoming
obese, allowing an early intervention. Moreover, the association between the data obtained from growth-curves
with specific metabolic risk factors further highlights the importance of these charts.
This study aimed to evaluate the associations between body mass index z-score (BMIzsc), determined using the
growth-curves from the Centre for Disease Control and Prevention (CDC) and from the World Health Organization
(WHO), with cardiovascular risk factors, represented here by metabolic syndrome (MS) and insulin resistance (IR)
related parameters.
The study involved 246 obese adolescents (10–18 years, 122 females). MS was defined according to the
International Diabetes Federation. IR was considered for HOMA-IR greater than 2.5.
Findings: No difference between both BMIzsc in identifying MS was noticeable by a ROC analysis. For both indexes
the area-under-the-curve increased for older groups, particularly for males.
CDC-BMIzsc was the best predictor of MS by logistic regression when all population was considered, however MS
was better predicted by WHO-BMIzsc for females and by CDC-BMIzsc for males. Younger girls and older boys were
in increased risk for MS. Similar results were obtained for IR.
Conclusions: A significant difference between the two BMIzsc regarding their association with MS and IR was not
clear, being these associations weaker in younger individuals.
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Introduction
Pediatric obesity is an important problem in Portugal
with almost one third of Portuguese children and ado-
lescents being overweight or obese [1-3]. As obesity is
associated with increased metabolic and cardiovascular* Correspondence: luisbelo@ff.up.pt
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unless otherwise stated.risk [4], it is important to accurately evaluate the nutri-
tional status in pediatrics and identify individuals in risk
in order to intervene as soon as possible.
During childhood body mass index (BMI) is adjusted
for age and gender defining the BMI z-score (BMIzsc).
Two of the most used BMI-based criteria to evaluate the
nutritional status are those from the Centre for Disease
Control and Prevention (CDC) and from the World
Health Organization (WHO) [5]. These criteria have
different base population, leading to different growth-
curves and cut-offs. In fact, for a given population,ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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obese and reduced percentage of under-weight when
compared to CDC-BMIzsc [1].
In Portugal the CDC criterion was recommend by the
Portuguese Ministry of Health until 2012, being the cri-
terion from WHO the recommended since 2013 [6]. It is
necessary to evaluate how this change influences this
tool efficacy in characterizing the nutritional status.
Furthermore, rises in both BMIzsc, have been associ-
ated with increased cardiovascular risk factors [7,8].
Nevertheless, there is limited information regarding
how the relation between BMIzsc and biochemical
variables is affected by this change, and if there is any
statistical advantage in choosing one criterion over the
other.
This study aimed to evaluate the differences in BMIzsc
determined using the criteria of CDC and WHO [9,10],
and their relation with cardiovascular risk factors, repre-
sented here by metabolic syndrome (MS) and insulin re-
sistance (IR) related parameters.
Methods
The study involved 246 obese adolescents (10–18
years, 122 females) identified from medical records
from two Porto hospitals (Portugal). Anthropometric
and biochemical markers were determined as described
elsewhere [11]. Participant’s BMIzsc were classified ac-
cording to WHO [10] and CDC [9] criteria.
The participants were classified as presenting or
not MS according to the International Diabetes
Federation [12].
The population was also divided in presenting or not
IR according to having a homeostasis model of insulin
resistance (HOMA-IR) greater than 2.5 [13,14].
The distributions of continuous variables were an-
alyzed using Kolmogorov-Smirnov tests to assess
significant departures from normality. Normally
distributed variables are presented as mean ± SD
(standard deviation) and those non-normally distrib-
uted are presented as median (interquartile range).
Variables non-normally distributed were log transformed
before further analysis.
Comparisons between two groups were performed
using Student’s unpaired t-test. The association between
categorical variables was analyzed using chi-squared test
and Fisher’s exact test.
The strength of the association between the variables
was estimated by Pearson correlation coefficient.
To evaluate the agreement between the BMIzsc de-
fined according to the WHO and the CDC criteria a
Bland–Altman analysis was performed.
The population was divided according to the following
age groups: Group 1: males < 13 and females < 12 years;
Group 2: males ≥ 13 and females ≥ 12 years.To evaluate the association of MS with the two
BMIzsc criteria a receiver operating characteristic (ROC)
analysis was performed.
A stepwise logistic regression analysis with MS or IR as
the dependent variable, and an entry criteria of P <0.05,
was also performed involving the two BMIzsc as inde-
pendent variables, while controlling for age and gender.
Both the ROC and the logistic regression analysis were
repeated while dividing the population according to gen-
der and age groups.
Statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS, version 21.0) for
Windows (SPSS Inc., Armonk, NY, USA). Statistical sig-
nificance was accepted at P less than 0.05.
Results
The population characteristics are resumed in Table 1.
The individual correlations between the two BMIzsc and
the different metabolic markers were similar being the
highest correlations found with waist-to-height ratio and
insulin. Regarding the MS groups, there was no differ-
ence in gender and Tanner stage distributions.
Figure 1 presents a Bland–Altman plot between WHO
and CDC BMIzsc. This type of analysis can be used to
evaluate the agreement between two methods/assays
that quantify the same variable. It can be observed that
the difference between the scores increases with the in-
crease of their average; thus, these scores will classify
subjects differently, especially for larger BMIzsc.
No difference between both BMIzsc in identifying MS
was noticeable concerning ROC analysis (Table 2). There
was also no difference when the same analysis was
repeated further stratifying the population according to
gender and age groups. BMIzsc from both criteria did
not seem to associate with MS for the younger individ-
uals, both when considered together or separated by
gender (particularly in males), contrarily to older indi-
viduals (Table 2).
The variable that entered the model in the stepwise lo-
gistic regression analysis for MS with the two BMIzsc as
independent variables when all population was con-
sidered, while controlling for age and gender, was
CDC-BMIzsc (Table 2). Afterwards the analysis was
repeated according to gender, being the presence of
MS better predicted by WHO-BMIzsc for females,
while by CDC-BMIzsc for males. When the analysis was
made considering the age groups, no variable entered the
model for the younger subjects, both when considered all
together or separated by genders. For the older group the
associations mimicked the ones seen for the whole popu-
lation (data not shown).
The logistic regression analysis also revealed that
younger girls are in a slightly increased risk for MS,
while for males the effect of aging is the opposite, with
Table 1 Comparison between clinical and biochemical data of obese children and adolescents based on the presence
of metabolic syndrome and the correlation of anthropometric and metabolic variables with BMI z-score defined
according to CDC or WHO criteria
Correlation with BMI z-score1)
Without MS With MS P2) WHO CDC
Number of participants (%) 185 (75.2) 61 (24.8) - - -
Females, n (%) 97 (52.4) 25 (41.0) 0.141 - -
Pubertal Stage (pre-pub (%))3) 30 (16.2) 8 (13.1) 0.684 - -
Age (years) 12.7 ± 1.8 13.4 ± 2.1 0.017 0.057 0.122
Height (cm) 158.5 ± 8.9 162.8 ± 9.9 0.002 0.189** 0.277**
Weight (kg) 78.0 (68.0-89.0) 90.2 (76.0-113.5) <0.001 0.673** 0.726**
BMI (kg/m2) 30.55 (28.15-34.08) 34.52 (30.20-39.14) <0.001 0.848** 0.865**
BMI z-score (CDC) 2.20 ± 0.29 2.43 ± 0.31 <0.001 0.933** -
BMI z-score (WHO) 3.00 ± 0.62 3.51 ± 0.86 <0.001 - 0.933**
Waist circumference (cm) 99.0 (91.8-106.5) 105.0 (96.5-118.0) <0.001 0.736** 0.778**
Waist / Height 0.630 ± 0.066 0.668 ± 0.081 0.002 0.794** 0.783**
Blood pressure
Systolic (mmHg)4) 116 ± 12 135 ± 13 <0.001 0.323** 0.360**
Diastolic (mmHg)4) 63 ± 8 70 ± 12 0.001 0.267** 0.218**
Lipid profile
TG (mg/dl) 71.0 (53.1-100.6) 126.7 (81.5-181.5) <0.001 0.186** 0.185**
HDLc (mg/dl) 43.0 (38.3-49.0) 35.0 (32.0-38.4) <0.001 −0.215** −0.223**
TC (mg/dl) 150.8 (134.5-174.0) 164.0 (142.0-189.2) 0.038 0.105 0.084
LDLc (mg/dl) 92.0 (76.0-109.8) 101.0 (83.5-119.4) 0.055 0.145* 0.126*
Glucose metabolism
Glucose (mg/dl) 83.0 (77.0-89.6) 88.0 (80.0-93.8) 0.005 0.043 0.046
Insulin (μU/ml) 15.9 (12.2-22.1) 23.3 (14.6-33.3) <0.001 0.421** 0.440**
HOMA-IR 3.18 (2.43-4.52) 4.94 (3.34-7.06) <0.001 0.410** 0.429**
Inflammatory mediator
CRP (mg/l)5) 1.61 (0.84-4.05) 2.30 (1.00-4.59) 0.072 0.326** 0.302**
*, P < 0.05; **, P < 0.001; 1)Pearson correlations; 2)With MS vs. Without MS groups; 3)Pre-pubertal defined as Tanner stage = 1; 4)With MS n = 45, without MS n = 172;
5)With MS n = 60, without MS, n = 180; BMI, body mass index; CDC, Center for Disease Control and Prevention; CRP, c-reactive protein; HDLc, high density
lipoprotein cholesterol; HOMA-IR, homeostasis model of assessment-insulin resistance; LDLc, low density lipoprotein cholesterol; MS, metabolic syndrome;
pre-pub, pre-pubertal; TC, total cholesterol; TG, triglycerides; WHO, World Health Organization.
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Puberty interfere with the metabolic status differently
according to gender. Indeed, features of MS, as lipid
profile, fat distribution, blood pressure, insulin sensi-
tivity, vary through pediatric ages, with a particularly
strong fluctuation during puberty, while pre-pubertal
sexual differences are usually moderate or absent
[12,15,16]. After puberty, the differences in sexual hor-
mones seem to relate to the less atherogenic lipid pro-
file and improved inflammatory status presented by
females when compared to males. These changes in
inflammatory factors, particularly mediators closely
associated with IR and MS could explain part of the
gender-related differences. In fact, post-puberty girls (vs.
boys) present an inflammatory status, characterized byincreased adiponectin and reduced C-reactive protein,
that is linked with reduced IR and improved plasmatic
lipids [17,18].
A similar analysis was made replacing MS by IR and
dividing the population in presenting or not IR accord-
ing to having a HOMA-IR greater than 2.5 [13,14]. The
results were similar to the ones obtained for MS, never-
theless, CDC-BMIzsc was the best predictor of IR for all
groups (except for young males, for whom neither
BMIzsc entered the model, data not shown) (Table 2).
Limitations of the study
This study presents some limitations, namely: it was lim-
ited to a geographical region (Northern Portugal) and
only obese individuals were included. In this way, it is
Figure 1 Bland–Altman plot of the difference in BMI z-score
measured according to the World Health Organization (WHO)
and the Center for Disease Control and Prevention (CDC)
against the average of the measured BMI z-score. Horizontal
lines represent mean ± 2 standard deviation. Difference was
calculated WHO BMI z-score – CDC BMI z-score.
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populations or normal weight individuals.Conclusion
Concluding, it does not seem to exist a significant differ-
ence between the BMIzsc calculated according to the
WHO or the CDC criteria regarding their relation with
metabolic markers or power to predict MS or IR inTable 2 Association of BMI z-score calculated according to W
resistance (based on receiver operating characteristic (ROC) a
ROC
WHO
AUC
Metabolic syndrome
Total population (n = 246; MS = 61) 0.680**
Male Age group 1 (n = 57; MS = 9) 0.508
Male Age group 2 (n = 67; MS = 27) 0.763**
Female Age group 1 (n = 39; MS = 12) 0.642
Female Age group 2 (n = 83; MS = 13) 0.693*
Insulin resistance
Total population (n = 246; IR = 190) 0.655**
Male Age group 1 (n = 57; IR = 39) 0.551
Male Age group 2 (n = 67; IR = 53) 0.720*
Female Age group 1 (n = 39; IR = 32) 0.777**
Female Age group 2 (n = 83; IR = 66) 0.696*
*, P< 0.05; **, P< 0.001; 1)adjusted for age groups; insulin resistance defined as HOMA-IR
Federation; age group 1: males <13 years and females <12 years; age group 2: males ≥ 1
Control and Prevention; CI, confidence interval; IR, insulin resistance; ROC, Receiver operobese Portuguese adolescents. In the younger individ-
uals, the association between BMIzsc and MS or IR
seems to be weaker or not yet present, especially in
males. For older individuals there might be a slight
better association between CDC-BMIzsc and IR for all
groups, while MS seems to associate better with WHO-
BMIzsc for females and with CDC-BMIzsc for males. An
increased risk for MS for older males and younger females
also appears to be present, highlighting the importance of
an early intervention. This is, to the best of our knowledge,
the first paper to describe the increased risk of MS for
younger female adolescents. A protective effect of female
sexual hormones, particularly estrogens, against cardiovas-
cular risk has been long discussed [19]. In fact, it seems to
exist a down regulation of visceral adipose tissue related
oxidative stress and inflammation by estrogens, particularly
in obese individuals [19,20]. Nevertheless, other articles
point to a negative effect of puberty on cardiovascular risk
in both males and females [21]. Further studies are needed
to clarify the influence of puberty itself and pre-pubertal
development in future cardiovascular disease risk.
The growth-curves are an everyday instrument for the
pediatricians to follow the child/adolescent development.
Although the WHO criterion was built to be better ad-
justed to populations with different backgrounds, it does
not seem to present many differences to CDCs’ regarding
the relation with metabolic risk markers. Moreover, the
use of different criteria can lead to different epidemiologic
data even without effective variation in the population be-
ing present. Thus, studies before and after the adoption of
the new criteria should be carefully compared.HO and CDC criteria with metabolic syndrome and insulin
nd logistic regression analysis)
Logistic Regression1)
CDC
expB (95% CI)
0.703** CDC 15.66** (5.16-47.59)
0.543
CDC 17.55** (3.90-79.06); Age* 3.65 (1.14-11.70)
0.788**
0.636
WHO 2.76* (1.36-5.60); Age* 0.39 (0.15-0.99)
0.664
0.680** CDC 10.86** (3.64-32.46)
0.582
CDC 8.18* (1.97-33.96)
0.739*
0.777**
CDC 21.77** (3.76-126.02)
0.689*
≥ 2.5; metabolic syndrome defined according to the International Diabetes
3 years, females ≥ 12 years; AUC, area under the curve; CDC, Center for Disease
ating characteristic; MS, metabolic syndrome; WHO, World Health Organization.
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